[go: up one dir, main page]

AU2001289034A1 - Novel pdes and uses thereof - Google Patents

Novel pdes and uses thereof

Info

Publication number
AU2001289034A1
AU2001289034A1 AU2001289034A AU8903401A AU2001289034A1 AU 2001289034 A1 AU2001289034 A1 AU 2001289034A1 AU 2001289034 A AU2001289034 A AU 2001289034A AU 8903401 A AU8903401 A AU 8903401A AU 2001289034 A1 AU2001289034 A1 AU 2001289034A1
Authority
AU
Australia
Prior art keywords
nucleic acid
acid molecules
novel pde
novel
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289034A
Inventor
Joseph A. Beavo
Natalie Glavas
Kewei Gong
Stefan Kunz
Ana Rascon
Thomas Seebeck
Scott Haydn Soderling
Roya Zoraghi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001289034A1 publication Critical patent/AU2001289034A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.
AU2001289034A 2000-09-12 2001-09-12 Novel pdes and uses thereof Abandoned AU2001289034A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23244500P 2000-09-12 2000-09-12
US60/232,445 2000-09-12
US24050000P 2000-10-12 2000-10-12
US60/240,500 2000-10-12
PCT/US2001/028503 WO2002022661A2 (en) 2000-09-12 2001-09-12 NOVEL PDEs AND USES THEREOF

Publications (1)

Publication Number Publication Date
AU2001289034A1 true AU2001289034A1 (en) 2002-03-26

Family

ID=26925998

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289034A Abandoned AU2001289034A1 (en) 2000-09-12 2001-09-12 Novel pdes and uses thereof

Country Status (6)

Country Link
US (2) US7138259B2 (en)
EP (1) EP1317553B1 (en)
AT (1) ATE373717T1 (en)
AU (1) AU2001289034A1 (en)
DE (1) DE60130565D1 (en)
WO (1) WO2002022661A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138259B2 (en) * 2000-09-12 2006-11-21 University Of Washington PDEs and uses thereof
EP1439221B1 (en) * 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag PDE core construct
US7785849B2 (en) * 2003-09-05 2010-08-31 University Of Bern Cyclic nucleotide-specific phosphodiesterases from Leishmania and uses thereof
BRPI0414886A (en) 2003-09-29 2006-12-12 Topigen Pharma Inc oligonucleotide compositions and methods for treating disease including inflammatory conditions
US20090105281A1 (en) * 2006-04-27 2009-04-23 Paul Epstein Methods of treating inflammation
KR20090035662A (en) 2006-05-19 2009-04-10 토피겐 파마슈티컬스 인코포레이티드 Oligonucleotides Influencing Expression of Phosphodiesterases
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
JP2024500919A (en) * 2020-12-23 2024-01-10 ジェンザイム・コーポレーション Deuterated colony stimulating factor-1 receptor (CSF-1R) inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358535A (en) * 1980-12-08 1982-11-09 Board Of Regents Of The University Of Washington Specific DNA probes in diagnostic microbiology
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
DE3513168A1 (en) * 1985-04-12 1986-10-16 Thomas 8000 München Dandekar BIOSENSOR CONSISTING OF A SEMICONDUCTOR BASED ON SILICON OR CARBON-BASED (ELECTRONIC PART) AND NUCLEIN BASE (OR. OTHER BIOL. MONOMERS)
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
US5080548A (en) * 1990-07-05 1992-01-14 Columbia Trailer Co., Inc. Trailer dumper
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US6080548A (en) * 1997-11-19 2000-06-27 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US5798246A (en) * 1996-03-25 1998-08-25 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterase
US5932465A (en) * 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
US5922595A (en) * 1997-12-09 1999-07-13 Incyte Pharmaceuticals, Inc. Cyclic GMP phosphodiesterase
WO2001083796A2 (en) * 2000-05-03 2001-11-08 University Of Washington Adenoviral vectors for tumor specific gene expression and uses thereof
US7138259B2 (en) * 2000-09-12 2006-11-21 University Of Washington PDEs and uses thereof

Also Published As

Publication number Publication date
US20070116705A1 (en) 2007-05-24
EP1317553B1 (en) 2007-09-19
US20050058998A1 (en) 2005-03-17
ATE373717T1 (en) 2007-10-15
WO2002022661A3 (en) 2003-03-13
US7138259B2 (en) 2006-11-21
US7598067B2 (en) 2009-10-06
WO2002022661A2 (en) 2002-03-21
DE60130565D1 (en) 2007-10-31
EP1317553A2 (en) 2003-06-11

Similar Documents

Publication Publication Date Title
AU2002305450A1 (en) Proteomimetic compounds and methods
WO1997035989A3 (en) Cyclic nucleotide phosphodiesterase
AU2001289034A1 (en) Novel pdes and uses thereof
GB9924957D0 (en) Novel treatment
DK1025236T3 (en) Human checkpoint kinase, HCDS1, preparations and methods
MXPA05011085A (en) Compositions and methods relating to stop-1.
WO1998011234A3 (en) Human protein kinases
DK1234025T3 (en) Human enzymes from the metalloprotease family
WO2002008257A3 (en) Siglec (sialic acid-binding ig-related lectin) polypeptides and uses thereof
EP1265073A3 (en) Methods for determining plasma free drug concentration
NO20006026L (en) Methods and compositions for modulating angiogenesis using tyrosine kinase SRC
WO1999063094A3 (en) Nucleotide and protein sequences of gpr1 and methods based thereon
WO2002062964A3 (en) Ap1 amine oxidase variants
EP1578953A4 (en) Process for the determination of the primary structure of the messenger rna coding for the human recombinant endooligopeptidase a (heopa) ¬af217798|...
TW200517125A (en) Pharmaceutical composition for treatment of solid cancers
DE60333747D1 (en) DNA ENZYME FOR INHIBITING PLASMINOGENACTIVATOR INHIBITOR-1
WO1999055885A3 (en) Novel serine protease capable of selective cleavage of insulin-like growth factor binding protein
WO2002074930A3 (en) Trans inteins for protein domain shuffling and biopolymerization
Murase et al. Characterization of three types of aspartase activated by site-directed mutagenesis, limited proteolysis, and acetylation
WO2002036741A3 (en) Polynucleotide encoding an activated human t-lymphocyte-derived protein related to ubiquitin conjugating enzyme
NZ510812A (en) Novel peptides
WO2001059114A3 (en) Tumor suppressor gene, p47ing3
WO2005003289A3 (en) Ap1 amine oxidase variants
WO2000065055A3 (en) Human transporter proteins
WO2003002066A3 (en) Glycosylated kinamycins and methods of making and using them